Could a common diabetes drug protect arteries in type 1 diabetes?
NCT ID NCT04583462
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether metformin, a drug used for type 2 diabetes, can slow the buildup of calcium in leg arteries of people with type 1 diabetes. 230 adults will take either metformin or a placebo for two years. The goal is to see if metformin reduces artery hardening, which can lead to heart problems and amputations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin
What this could lead to
If it works, this could point toward a way to reduce dangerous artery hardening in people with type 1 diabetes, potentially lowering heart and limb risks.
What could go wrong
This is a phase 3 trial, but metformin is already widely used for type 2 diabetes. It may not work for this specific complication, and side effects like stomach upset are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pitié Salpêtrière Hospital, AP-HP, Diabetology department
Paris, 75013, France